News Equasens

Equities

EQS

FR0012882389

Real-time Euronext Paris Other stock markets 08:48:25 2024-04-26 am EDT			5-day change	1st Jan Change
58.7 ^EUR	-1.34%		+1.55%	-3.44%

Apr. 02	Equasens : RNPG virtually stable in 2023	CF
Mar. 29	Equasens Société Anonyme Provides Revenue Guidance for the 2025	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Equasens : RNPG virtually stable in 2023	Apr. 02	CF
Equasens: 2023 Annual Results	Mar. 29	GL
Equasens Société Anonyme Provides Revenue Guidance for the 2025	Mar. 29	CI
Equasens Société anonyme Proposes Gross Dividend	Mar. 29	CI
Equasens: annual sales growth of almost 3%	Feb. 07	CF
Equasens: 2023 revenue: €219.7m, +2.6%	Feb. 06	GL
Equasens Société Anonyme Reports Consolidated Revenue Results for the Fourth Quarter and Full Year of 2023	Feb. 06	CI
Global markets live: Airbus, Tesla, HSBC, KKR, Pfizer...	Jan. 03
Equasens to Acquire 70% Stake in Digipharmacie	Jan. 02	MT
Equasens: acquires 70% stake in Digipharmacie	Jan. 02	CF
Equasens: Acquisition of a majority stake in DIGIPHARMACIE	Jan. 02	GL
Equasens Société anonyme acquired 70% stake in Digipharmacie.	Jan. 01	CI
Equasens: changes to the management committee	Dec. 27	CF
Equasens Group Announces Management Appointments, Effective 1 January 2024	Dec. 27	CI
Equasens: Changes in the Equasens Group Executive Committee	Dec. 27	GL
CAC40: up slightly, stalls at the 7300 pts mark	Nov. 24	CF
Equasens: share price up, broker confirms its recommendation	Nov. 24	CF
EQUASENS : Stifel maintains its recommendation on the share	Nov. 24	CF
Equasens: acquisition of German company ADV	Nov. 24	CF
Equasens, Arz Haan Buy German Pharmacy Software Group Apotheken Datenverarbeitung	Nov. 24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer